PIPELINE
Focused & Derisked Strategy
Il-17 A/F
Indication:
Mild-Moderate Psoriasis
Soluble-FasL
Indication:
Pemphigus, SJS/TEN
Il-17 Bi-specific
Indication:
Psoriasis, PA, HS
TH2 Tri-Specific
Indication:
TH2 diseases (AD, Asthma, COPD)
Immunization
Selection
Clones Generation
In vitro/Ex vivo Efficacy
In Vivo
Proof-of-Concept
Toxicology
Phase 1/2
Primary Platform Validator
NanoAb, local intradermal admin
H1 2027 YE 2027
Flagship Value Driver
mAb
TBD TBD
Selective Innovation Track
NanoAb, systematic bi-specific
H2 2027 YE 2028
Future Optionality
NanoAb
H2 2027 YE 2028
Drug Candidate
A Dual-Platform, De-Risked Strategy
Scinai’s pipeline is built on the power of a dual strategy, combining NanoAbs and monoclonal antibodies (mAbs) to execute a focused, de-risked approach to product development across large and underserved markets.
NanoAbs: Precision, Efficacy, and Capital Efficiency
The NanoAb platform provides a validated and capital-efficient development path, delivering biologic-level efficacy through localized administration to minimize systemic side effects.
This strategy is anchored by a lead asset targeting the significantly underserved psoriasis population—representing approximately 50% of patients and a $10B+ market in 2024.
mAbs: First-in-Class Innovation in Severe Skin Disorders
Complementing the NanoAb platform, Scinai is advancing a novel, first-in-class, fully human anti-FasL monoclonal antibody designed to treat severe skin disorders such as Pemphigus, Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), and other high-unmet-need dermatologic indications, leveraging a unique, non-immunosuppressive mechanism of action.
Multiple Blockbuster Opportunities
With positive proof-of-concept data across its lead programs, proven regulatory pathways, and strong external validation for both NanoAb and mAb products, Scinai’s dual approach creates multiple blockbuster-scale opportunities while preserving strategic and financing optionality.
Contact us
Get in touch to explore partnership opportunities and consult our CDMO specialists